Ion337

Preclinical

Ionis Pharmaceuticals

Ion337 is one of 6 therapeutic programs targeting Dravet syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Dravet SyndromeRecruiting

Dravet SyndromePreclinical

Recruiting

Competition

Competitive Landscape

5 competitors in Dravet Syndrome

#DrugCompanyPhaseTrials

Fintepla

IImmedica Pharma AB

Approved

2 2

Fintepla

UCB

Approved

3 3

Zorevunersen

SStoke Therapeutics, Inc

Phase 3

2 4

ETX101

EEncoded Therapeutics

Phase 2

3 5

Diacomit

BBiocodex

Preclinical

4 6

Ion337

Ionis Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

PreclinicalRecruiting

Dravet Syndrome

NCT07531745

Clinical

Trials by Indication[1]

Dravet syndrome1 trial

Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients With Dravet Syndrome

Recruiting· Ionis Pharmaceuticals logo

Ionis Pharmaceuticals·Preclinical·NCT07531745·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ion337. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ion337. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Ionis Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: Ionis Pharmaceuticals

Ion337

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Dravet syndrome1 trial

References

Drug Info

Quick Facts

Related News